Presentations -
-
Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC International coauthorship International conference
Viteri S., Mazieres J., Veillon R., Felip E., Le X., Garassino M., Stanton T., Morise M., Lee J. -S., Matsumoto S., De Marinis F., Wehler T., Clark A., Friese-Hamim M., Stroh C., Bruns R., Otto G., Paik P.
JOURNAL OF THORACIC ONCOLOGY 2021.1
-
Short Hydration Regimen with a Modified Dose of Magnesium Supplementation for Lung Cancer Patients Receiving Cisplatin-Based Chemotherapy International conference
Hase T., Miyazaki M., Ichikawa K., Yogo N., Ozawa N., Ando M., Morise M., Sato M., Kondo M., Yamada K., Hasegawa Y.
JOURNAL OF THORACIC ONCOLOGY 2018.10
-
Serum CRP Decrease Has Predictive Value for LongTerm Disease Control by PD-1/ PD-L1 Inhibitors in Patients with NSCLC International conference
Matsuzawa R., Morise M., Tanaka I., Koyama J., Kimura T., Kondoh Y., Hase T., Sakamoto K., Hashimoto N., Hasegawa Y.
JOURNAL OF THORACIC ONCOLOGY 2019.10
-
Risk Factor Evaluation of Programmed Death 1 Inhibitor Related Pneumonitis in Patients with Non-Small Cell Lung Cancer International conference
Fukihara J., Sakamoto K., Iwano S., Morise M., Hashimoto N., Hasegawa Y.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2018
-
PREDICT1: An observational study for identifying blood biomarkers associated with clinical benefit from carboplatin and pemetrexed (CbP) treatment in patients with non-squamous (NS) non-small cell lung cancer (NSCLC) (CJLSG1201). International conference
Hase Tetsunari, Yanagisawa Kiyoshi, Fukatsu Asuki, Kimura Tomoki, Kojima Eiji, Abe Takashi, Imaizumi Kazuyoshi, Horio Yoshitsugu, Oguri Tetsuya, Yamamoto Masashi, Ogasawara Tomohiko, Sugino Yasuteru, Morise Masahiro, Nakatochi Masahiro, Ando Masahiko, Kondo Masashi, Saka Hideo, Saito Hiroshi, Hasegawa Yoshinori, Takahashi Takashi
JOURNAL OF CLINICAL ONCOLOGY 2020.5.20
-
Phase II study of tepotinib in NSCLC patients with METex14 mutations. International coauthorship International conference
Paik Paul K., Veillon Remi, Cortot Alexis B., Felip Enriqueta, Sakai Hiroshi, Mazieres Julien, Griesinger Frank, Horn Leora, Senellart Helene, Van Meerbeeck Jan P., de Castro Carpeno Javier, Patel Jyoti D., Garassino Marina Chiara, Morise Masahiro, Reinmuth Niels, Viteri Santiago, Tokito Takaaki, Sakamoto Tomohiro, Scheele Juergen, Le Xiuning
JOURNAL OF CLINICAL ONCOLOGY 2019.5.20
-
Phase II study of gedatolisib for small-cell lung cancer (SCLC) patients (pts) with genetic alterations in PI3K/AKT/mTOR pathway based on a large-scale nationwide genomic screening network in Japan (EAGLE-PAT/LC-SCRUM-Japan). International conference
Udagawa Hibiki, Ikeda Takaya, Umemura Shigeki, Daga Haruko, Toyozawa Ryo, Harada Daijiro, Sakakibara-Konishi Jun, Morise Masahiro, Yamamoto Noboru, Takahashi Toshiaki, Kato Terufumi, Shingyoji Masato, Ushio Ryota, Hara Satoshi, Takata Saori, Nomura Shogo, Matsumoto Shingo, Niho Seiji, Sato Akihiro, Goto Koichi
JOURNAL OF CLINICAL ONCOLOGY 2020.5.20
-
Phase II study of crizotinib in Japanese patients with advanced non-small cell lung cancer harboring a MET gene alteration: Co-MET study International conference
Shimokawa M., Nosaki K., Seto T., Ohashi K., Morise M., Fujiwara Y., Sakakibara J., Murakami H., Yano S., Satouchi M., Matsumoto S., Goto K., Yoh K.
ANNALS OF ONCOLOGY 2019.4
-
IMPOWER110: INTERIM OVERALL SURVIVAL (OS) ANALYSIS OF A PHASE III STUDY OF ATEZOLIZUMAB (ATEZO) MONOTHERAPY VS PLATINUM-BASED CHEMOTHERAPY (CHEMO) AS FIRST-LINE (1L) TREATMENT IN PD-L1-SELECTED NSCLC International coauthorship International conference
Herbst Roy, De Marinis Filippo, Giaccone Giuseppe, Reinmuth Niels, Vergnenegre Alain, Barrios Carlos, Morise Masahiro, Font Enriqueta, Andric Zoran, Geater Sarayut, Ozguroglu Mustafa, Mocci Simonetta, McCleland Mark, Enquist Ida, Komatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Spigel David
JOURNAL FOR IMMUNOTHERAPY OF CANCER 2020.4
-
Impower110: Interim OS Analysis of a Phase III Study Of Atezolizumab (ATEZO) vs Platinum-Based Chemotherapy (Chemo) as 1L Treatment (TX) in PD-L1-Selected NSCLC International coauthorship International conference
Reinmuth Niels, Spigel David, De Marinis Filippo, Giaccone Giuseppe, Verynenegre Alain, Barrios Carlos Henrique, Morise Masahiro, Felip Enriqueta, Andric Zoran, Geater Sarayut, Ozgueroglur Mustafa, Mocci Simonetta, Mccleland Mark, Enquist Ida, Kotnatsubara Kim, Deng Yu, Kuriki Hiroshi, Wen Xiaohui, Jassem Jacek, Herbst Roy S.
ONCOLOGY RESEARCH AND TREATMENT 2020.2
-
Impact Of Mild To Moderate COPD On Prognosis And Feasibility For Chemotherapy In Patients With Lung Cancer
Omote N., Hashimoto N., Morise M., Miyazaki S., Ando A., Hasegawa Y.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE 2017
-
Impact of Combined Evaluation Using Tumor Volume and Metastatic Nodal Extent in Stage III NSCLC Treated with CRT International conference
Tamiya Y., Morise M., Matsuzawa R., Tanaka I., Okada T., Iwano S., Hase T., Hashimoto N., Sato M., Itoh Y., Hasegawa Y.
JOURNAL OF THORACIC ONCOLOGY 2019.10
-
Immune checkpoint inhibitor for advanced or recurrent non-small cell lung cancer patients with poor performance status International conference
Koyama Junji, Kimura Tomoki, Oi Hajime, Yamano Yasuhiko, Yokoyama Toshiki, Matsuda Toshiaki, Kataoka Kensuke, Matsuzawa Reiko, Fukihara Jun, Sakamoto Koji, Morise Masahiro, Hashimoto Naozumi, Kondoh Yasuhiro, Hasegawa Yoshinori
ANNALS OF ONCOLOGY 2019.10
-
Identification of Proteosomal Catalytic Subunit PSMA6 as a Therapeutic Target for Lung Cancer through a Pooled shRNA Screen International conference
Sato M., Kakumu T., Goto D., Kato T., Yogo N., Hase T., Morise M., Fukui T., Yokoi K., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.
JOURNAL OF THORACIC ONCOLOGY 2017.11
-
Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK plus NSCLC). International conference
Seto Takashi, Nishio Makoto, Hida Toyoaki, Nokihara Hiroshi, Morise Masahiro, Kim Young Hak, Azuma Koichi, Takiguchi Yuichi, Yoshioka Hiroshige, Kumagai Toru, Hotta Katsuyuki, Watanabe Satoshi, Goto Koichi, Satouchi Miyako, Kozuki Toshiyuki, Nakagawa Kazuhiko, Mitsudomi Tetsuya, Yamamoto Nobuyuki, Asakawa Takashi, Tamura Tomohide
JOURNAL OF CLINICAL ONCOLOGY 2019.5.20
-
eIF2 beta, A Subunit of Translation-Initiation Factor EIF2, as a Potential Therapeutic Target for Non-Small Cell Lung Cancer International conference
Goto D., Tanaka I., Sato M., Kato T., Miyazawa A., Hase T., Morise M., Sekido Y., Girard L., Minna J., Byers L., Heymach J., Coombes K., Kondo M., Hasegawa Y.
JOURNAL OF THORACIC ONCOLOGY 2018.10
-
Clinicopathological Significance of Cancer Stem-Like Cell Markers in High-Grade Neuroendocrine Carcinoma of the Lung International conference
Morise Masahiro, Hishida Tomoyuki, Takahashi Akiko, Yoshida Junji, Ohe Yuichiro, Nagai Kanji, Ishii Genichiro
JOURNAL OF THORACIC ONCOLOGY 2017.1
-
Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by SP142, SP263 and 22C3 PD-L1 immunohistochemistry (IHC) assays and by blood tumour mutational burden (bTMB): Results from the IMpower110 study International coauthorship International conference
Herbst R. S., de Marinis F., Giaccone G., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D. R., Jassem J.
ANNALS OF ONCOLOGY 2019.12
-
Clinical efficacy of atezolizumab (atezo) in biomarker subgroups by PD-L1 immunohistochemistry (IHC) assays and blood tumour mutational burden (bTMB): IMpower110 International coauthorship International conference
Herbst R. S., De Marinis F., Giaccone G., Stahel R., Reinmuth N., Vergnenegre A., Barrios C. H., Morise M., Felip E., Andric Z., Geater S., Ozguroglu M., Mocci S., McCleland M., Zou W., Enquist I., Komatsubara K., Deng Y., Kuriki H., Spigel D., Jassem J.
SWISS MEDICAL WEEKLY 2020.11.18
-
Alectinib in Previously Treated RET-Rearranged Advanced Non-Small-Cell Lung Cancer: A Phase 1/2 Trial (ALL-RET) International conference
Yanagitani N., Takeuchi S., Murayama T., Yoshimura K., Imai Y., Takahara S., Kawakami T., Seto T., Hattori Y., Ohashi K., Morise M., Matsumoto S., Yoh K., Goto K., Nishio M., Yano S.
JOURNAL OF THORACIC ONCOLOGY 2019.10